volrustomig + ramucirumab + carboplatin + paclitaxel

A combination regimen composed of **volrustomig** (a bispecific humanized monoclonal antibody targeting PD-1 and CTLA-4), **ramucirumab** (a monoclonal antibody targeting VEGFR2), **carboplatin** (a platinum-based chemotherapy), and **paclitaxel** (a microtubule inhibitor chemotherapeutic). This combination is under clinical investigation, notably in lung and thoracic malignancies, for its potential synergistic immunotherapeutic and cytotoxic anti-tumor effects. Volrustomig is developed to provide dual immune checkpoint blockade, ramucirumab inhibits tumor angiogenesis, and carboplatin plus paclitaxel constitute established standard-of-care chemotherapy backbones[3][5][7].